Study identifier:NIS-OAE-XXX-2011/1
ClinicalTrials.gov identifier:NCT01562665
EudraCT identifier:N/A
CTIS identifier:N/A
Epidemiological study to describe NSCLC clinical management patterns in MENA
Non Small Cells Lung Cancer
N/A
No
-
All
25
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2016 by AstraZeneca
AstraZeneca
-
The overall aim of the study is: To provide accurate and reliable information regarding NSCLC clinical management across MENA region in order to detect unmet medical needs of this disease in terms of: - Patient and hospital characteristics. - Diagnostic and treatment approaches: initial and subsequent. - Follow-up patterns in clinical management. - Outcomes: symptoms, death, functionality, quality of life. - Use of resources and burden on patients and health care systems.
Epidemiological study to describe NSCLC clinical management patterns in MENA
Location
Location
Doha, Qatar
Location
Manama, Bahrain
Location
Alain - AbuAhabi, United Arab Emirates
Arms | Assigned Interventions |
---|---|
All Population | - |
Sample of patients will be invited to complete Quality of Life | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.